{"id":390650,"date":"2018-06-12T00:00:00","date_gmt":"2018-06-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0023-2018-biopharma-type-2-diabetes-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-04-30T23:44:12","modified_gmt":"2026-04-30T23:44:12","slug":"algomd0023-2018-biopharma-type-2-diabetes-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0023-2018-biopharma-type-2-diabetes-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Type 2 Diabetes | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p>Historically, metformin and the sulfonylureas were the most-prescribed drugs for type 2 diabetes. These agents dominated the early lines of therapy until disease progression required insulin replacement. However, the emergence of more-effective, safer, and\/or better-tolerated therapies, such as the dipeptidyl peptidase-4 (<abbr data-original-title=\"dipeptidyl peptidase-IV\" title=\"\">DPP-IV<\/abbr>) inhibitors, sodium glucose contransporter-2 (<abbr data-original-title=\"sodium glucose cotransporter\" title=\"\">SGLT<\/abbr>-2) inhibitors, and glucagon-like peptide-1 (<abbr data-original-title=\"glucagon-like peptide\" title=\"\">GLP<\/abbr>-1) receptor agonists, has provided physicians with a much broader array of therapeutic options. Moreover, because of a better understanding of type 2 diabetes and its complications, treatment is becoming more individualized. Numerous branded agents from both established and new drug classes are now jostling for position in the treatment paradigm.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the trends in prescribing among recentlytreated and newly diagnosed type 2 diabetes patients?<\/li>\n<li>How have Jardiance, Trulicity, and Tresiba been integrated into the treatment algorithm?<\/li>\n<li>What proportion of type 2 diabetes patients receives drug therapy within one year of diagnosis?<\/li>\n<li>What percentage of patients progresses to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of type 2 diabetes patients is treated with monotherapy versus combination therapy?<\/li>\n<li>What are the most widely used combination treatments?<\/li>\n<li>What are the compliance and persistency rates for type 2 diabetes therapies?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.<\/p>\n<p><strong>KEY DRUGS COVERED<\/strong><\/p>\n<p>Afrezza, Apidra, Basaglar, Bydureon, Byetta, Farxiga, Humalog, Invokana, Januvia, Jardiance, Lantus, Levemir, Metformin, Nesina, Novolog, Onglyza, Toujeo, Tradjenta, Tresiba, Trulicity, Victoza<\/p>\n<p><strong>KEY ANALYSIS PROVIDED<\/strong><\/p>\n<ul>\n<li>Brand use across a longitudinal patient sample.<\/li>\n<li>Newly diagnosed patient analysis.<\/li>\n<li>Treatment initiation and progression.<\/li>\n<li>Line of therapy analysis.<\/li>\n<li>Combination therapy analysis.<\/li>\n<li>Source of business for recently treated patients.<\/li>\n<li>Persistency and compliance analysis.<\/li>\n<li>Product-level patient flowcharts.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390650","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390650\/revisions"}],"predecessor-version":[{"id":393774,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390650\/revisions\/393774"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}